论文部分内容阅读
目的:分析总结XELOX方案(奥沙利铂+卡培他滨)治疗晚期老年结直肠癌的安全性及有效性。方法:对我科2004-2007年65岁以上、接受XELOX方案化疗、临床资料完整的24例晚期老年结直肠癌患者进行回顾性总结。结果:24例晚期老年结直肠癌患者中,结肠癌13例,直肠癌11例。其中合并高血压、冠心病、糖尿病等慢性病者12例(占50%)。共完成XELOX方案化疗92个周期。24例中完全缓解(CR)1例,部分缓解(PR)9例,稳定(SD)10例,进展(PD)4例,有效率(RR)41.7%。不良反应主要为胃肠道反应、骨髓抑制、手足综合征、腹泻等,均可耐受。结论:卡培他滨联合奥沙利铂治疗老年晚期结直肠癌疗效确切,不良反应轻,老年患者耐受性好,用药剂量和强度均无需减低。
Objective: To analyze the safety and efficacy of XELOX regimen (oxaliplatin + capecitabine) in the treatment of advanced colorectal cancer. Methods: A retrospective review was made on 24 patients with advanced colorectal cancer who were over 65 years of age in 2004-2007 who underwent XELOX regimen and had complete clinical data. Results: Of the 24 patients with advanced colorectal cancer, there were 13 cases of colon cancer and 11 cases of rectal cancer. Including hypertension, coronary heart disease, diabetes and other chronic diseases in 12 patients (50%). A total of 92 cycles of XELOX chemotherapy were completed. Among the 24 patients, there were 1 complete remission (CR), 9 partial remission (PR), 10 stable (SD) and 4 progressive (PD) patients. The response rate was 41.7%. Adverse reactions mainly gastrointestinal reactions, bone marrow suppression, hand-foot syndrome, diarrhea, etc., can be tolerated. Conclusion: Capecitabine combined with oxaliplatin is effective in the treatment of elderly patients with advanced colorectal cancer. The adverse reactions are mild and the elderly patients are well tolerated. There is no need to reduce the dosage and intensity of the drug.